Compile Data Set for Download or QSAR
Report error Found 209 Enz. Inhib. hit(s) with Target = 'Genome polyprotein [1027-1711]'
TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236571(US9365582, 13)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236566(US9365582, 7)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236565(US9365582, 5)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236563(US9365582, 3)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236573(US9365582, 15)
Affinity DataKi:  0.200nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229576(US9334279, 1052)
Affinity DataEC50:  0.300nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229547(US9334279, 1023)
Affinity DataEC50:  0.460nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236569(US9365582, 11)
Affinity DataKi:  0.5nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235861(US9364482, 36)
Affinity DataIC50: 0.527nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229567(US9334279, 1043)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229584(US9334279, 1060)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229565(US9334279, 1041)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229583(US9334279, 1059)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229564(US9334279, 1040)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229560(US9334279, 1036)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229559(US9334279, 1035)
Affinity DataEC50:  0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235836(US9364482, 10)
Affinity DataIC50: 0.768nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235890(US9364482, 71)
Affinity DataIC50: 0.782nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM236567(US9365582, 9)
Affinity DataKi:  0.800nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235855(US9364482, 29)
Affinity DataIC50: 0.886nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229541(US9334279, 1017)
Affinity DataEC50:  0.950nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235856(US9364482, 30)
Affinity DataIC50: 0.981nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235833(US9364482, 7)
Affinity DataIC50: 1.06nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235861(US9364482, 36)
Affinity DataIC50: 1.08nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235863(US9364482, 38)
Affinity DataIC50: 1.14nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235863(US9364482, 38)
Affinity DataIC50: 1.38nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM229529(US9334279, 1005)
Affinity DataEC50:  1.48nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235833(US9364482, 7)
Affinity DataIC50: 1.48nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235831(US9364482, 5)
Affinity DataIC50: 1.59nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235845(US9364482, 19)
Affinity DataIC50: 1.60nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235860(US9364482, 35)
Affinity DataIC50: 1.71nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235845(US9364482, 19)
Affinity DataIC50: 1.75nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235836(US9364482, 10)
Affinity DataIC50: 1.79nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235832(US9364482, 6)
Affinity DataIC50: 1.93nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235880(US9364482, 55)
Affinity DataIC50: 1.93nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235887(US9364482, 68)
Affinity DataIC50: 2.00nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235839(US9364482, 13)
Affinity DataIC50: 2.06nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235877(US9364482, 52)
Affinity DataIC50: 2.11nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235860(US9364482, 35)
Affinity DataIC50: 2.15nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235856(US9364482, 30)
Affinity DataIC50: 2.23nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235887(US9364482, 68)
Affinity DataIC50: 2.24nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235879(US9364482, 54)
Affinity DataIC50: 2.34nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235876(US9364482, 51)
Affinity DataIC50: 2.35nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235880(US9364482, 55)
Affinity DataIC50: 2.42nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235827(US9364482, 1)
Affinity DataIC50: 2.44nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235878(US9364482, 53)
Affinity DataIC50: 2.45nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235847(US9364482, 21)
Affinity DataIC50: 2.51nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235839(US9364482, 13)
Affinity DataIC50: 2.55nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Janssen Ireland

US Patent
LigandPNGBDBM235878(US9364482, 53)
Affinity DataIC50: 2.57nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetGenome polyprotein [1027-1711](HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM235850(US9364482, 24)
Affinity DataIC50: 2.57nMAssay Description:Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

Displayed 1 to 50 (of 209 total ) | Next | Last >>
Jump to: